CD4 and non-small cell lung carcinoma: Based on 74 advanced NSCLC patients treated with nivolumab, a higher density of CD4+ and CD8+ T cells was observed in responders at baseline [116], suggesting that a higher circulating T lymphocyte level may predict response to ICI.